Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381107 | 1.00 | MDM2 (0.53) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL29400768 | 1.00 | MDM2 (0.53) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL30954533 | 0.92 | MDM2 (0.51) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL30649315 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29768913 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29352017 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL120511 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL117964 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29792120 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29792372 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324210-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120022072-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022072-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100093742-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100016328-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016328-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7601717-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090176790-A1 | For treating conditions responsive to tetrahydrobiopterin therapies | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093742-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | MDM2 3765/4885IDO1 1139/4885TLR2 1098/4885 |
| US-20100016328-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | MDM2 3765/4885IDO1 1139/4885TLR2 1098/4885 |
| US-20120022072-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | MDM2 3765/4885IDO1 1139/4885TLR2 1098/4885 |
| US-20090176790-A1 | For treating conditions responsive to tetrahydrobiopterin therapies | TPMT, LTB4R2, BDKRB2 | MDM2 4502/4885IDO1 1288/4885TLR2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.